फलो गर्नुहोस्
Englishनेपाली
← पछाडि
औषधि · अन्तरक्रिया

Spironolactone — अन्तरक्रिया (Interactions)

अन्य औषधि, खाना र जडीबुटी उत्पादनले Spironolactone को काम बदल्न सक्छन्। यस पृष्ठका सबै कुरा Spironolactone कै FDA-स्वीकृत लेबलबाट आएका हुन् — मुख्य गाइडकै स्रोतबाट।

← पूरा Spironolactone गाइडमा फर्कनुहोस्

⚠ सावधानी: • Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia . • Lithium: Increased risk of lithium toxicity . • NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone . • Digoxin: Spironolactone can interfere with radioimmunologic assays of digoxin exposure . • Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use .

Spironolactone को लेबलमा नाम भएका औषधिहरू

लेबलले जसरी समूह बनाएको छ, त्यसरी नै राखिएको छ। प्रत्येक नाम त्यस औषधिको NepalDoc गाइडसँग जोडिन्छ; लेबलले औषधिको नाम नभई वर्ग मात्र भनेको ठाउँमा लेबलकै शब्द उद्धृत गरिएको छ।

Drugs and Supplements Increasing Serum Potassium

Concomitant administration of spironolactone with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. In general, discontinue potassium supplementation in heart failure patients who start spironolactone . Check serum potassium levels when ACE inhibitor or ARB therapy is altered in patients receiving spironolactone.

Lithium Like

Other diuretics, spironolactone reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity. Monitor lithium levels periodically when spironolactone is coadministered .

Nonsteroidal Anti-Inflammatory

Drugs (NSAIDs) In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effect of diuretics. Therefore, when spironolactone and NSAIDs are used concomitantly, monitor closely to determine if the desired effect of the diuretic is obtained .

लेबलको खण्ड 7.4

Digoxin Spironolactone and its metabolites interfere with radioimmunoassays for digoxin and increase the apparent exposure to digoxin. It is unknown to what extent, if any, spironolactone may increase actual digoxin exposure. In patients taking concomitant digoxin, use an assay that does not interact with spironolactone.

Cholestyramine Hyperkalemic

Metabolic acidosis has been reported in patients given spironolactone concurrently with cholestyramine.

Acetylsalicylic Acid

Acetylsalicylic acid may reduce the efficacy of spironolactone. Therefore, when spironolactone and acetylsalicylic acid are used concomitantly, spironolactone may need to be titrated to higher maintenance dose and the patient should be observed closely to determine if the desired effect is obtained .

लेबलको खण्ड 7.7

Abiraterone Spironolactone binds to the androgen receptor and may increase prostate-specific antigen (PSA) levels in abiraterone-treated prostate cancer patients. Concomitant use of spironolactone and abiraterone is not recommended.

Mitotane Avoid

Concomitant use of spironolactone and mitotane. Spironolactone reduces mitotane plasma levels .

Spironolactone को लेबलले ३ औषधिको नाम लिएको छ, जुन NepalDoc मा पनि छन्।

यहाँ नाम भएका औषधिका अन्तरक्रिया पृष्ठहरू

यहाँ नाम भएका यी औषधिका आफ्नै अन्तरक्रिया पृष्ठ पनि छन्:

Spironolactone को लेबलको पूरा अन्तरक्रिया खण्ड पढ्नुहोस्

• Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia . • Lithium: Increased risk of lithium toxicity . • NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone . • Digoxin: Spironolactone can interfere with radioimmunologic assays of digoxin exposure . • Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use . • Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of spironolactone . • Abiraterone: May increase prostate-specific antigen (PSA) levels . • Mitotane: Avoid concomitant use of spironolactone and mitotane .

7.1 Drugs and Supplements Increasing Serum Potassium Concomitant administration of spironolactone with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. In general, discontinue potassium supplementation in heart failure patients who start spironolactone . Check serum potassium levels when ACE inhibitor or ARB therapy is altered in patients receiving spironolactone. Examples of drugs that can increase potassium include: • ACE inhibitors • angiotensin receptor blockers • non-steroidal anti-inflammatory drugs (NSAIDs) • heparin and low molecular weight heparin • trimethoprim

7.2 Lithium Like other diuretics, spironolactone reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity. Monitor lithium levels periodically when spironolactone is coadministered .

7.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effect of diuretics. Therefore, when spironolactone and NSAIDs are used concomitantly, monitor closely to determine if the desired effect of the diuretic is obtained .

7.4 Digoxin Spironolactone and its metabolites interfere with radioimmunoassays for digoxin and increase the apparent exposure to digoxin. It is unknown to what extent, if any, spironolactone may increase actual digoxin exposure. In patients taking concomitant digoxin, use an assay that does not interact with spironolactone.

7.5 Cholestyramine Hyperkalemic metabolic acidosis has been reported in patients given spironolactone concurrently with cholestyramine.

7.6 Acetylsalicylic Acid Acetylsalicylic acid may reduce the efficacy of spironolactone. Therefore, when spironolactone and acetylsalicylic acid are used concomitantly, spironolactone may need to be titrated to higher maintenance dose and the patient should be observed closely to determine if the desired effect is obtained .

7.7 Abiraterone Spironolactone binds to the androgen receptor and may increase prostate-specific antigen (PSA) levels in abiraterone-treated prostate cancer patients. Concomitant use of spironolactone and abiraterone is not recommended.

7.8 Mitotane Avoid concomitant use of spironolactone and mitotane. Spironolactone reduces mitotane plasma levels .

Spironolactone गाइड · सबै अन्तरक्रिया पृष्ठहरू · औषधि A–Z

स्रोतU.S. FDA-approved label via DailyMed (label effective 29 Dec 2025) · National List of Essential Medicines, Nepal (2021) · अमेरिकी लेबलिङ नेपालको DDA-स्वीकृत लेबलिङ र स्थानीय प्रिस्क्राइबिङ अभ्यासभन्दा फरक हुन सक्छ।

यो पृष्ठले Spironolactone को FDA-स्वीकृत लेबलको सारांश जानकारीका लागि दिन्छ — यो चिकित्सकीय सल्लाह होइन। तपाईंले लिने हरेक औषधि, सप्लिमेन्ट र जडीबुटी उत्पादनबारे आफ्नो डाक्टर वा फार्मासिस्टलाई सधैं भन्नुहोस्।

एपमा औषधि खोज्नुहोस् फार्मेसी खोज्नुहोस्
+ सुरक्षा जानकारी

यो पृष्ठ सामान्य जानकारीका लागि मात्र हो, चिकित्सकीय सल्लाह होइन। औषधि प्रयोग गर्नुअघि डाक्टर वा फार्मासिस्टसँग सल्लाह लिनुहोस्। विवरण माथि उल्लेखित स्रोतहरूबाट आएको हो र परिवर्तन हुन सक्छ। NLEM सूचीमा हुनुले कुनै फार्मेसीमा औषधि उपलब्ध छ भन्ने ग्यारेन्टी दिँदैन।

यो औषधि सेयर गर्नुहोस्
NepalDoc — Nepal's Healthcare Super-App (Beta) / नेपालको स्वास्थ्य सुपर-एप (बेटा).
Medicine information only — not medical advice. Confirm with a pharmacist or doctor.